Q-omics provides the consensus-scored SUCLA2 profile across patient tissues and cancer cell-line models. SUCLA2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUCLA2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SUCLA2 protein abundance shows 26,593 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where SUCLA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUCLA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUCLA2 survival associations across molecular data types. SUCLA2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUCLA2 RNA expression–survival associations across cancer types. High SUCLA2 expression shows unfavorable associations in BLCA, CESC, ESCA and MESO, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUCLA2 RNA expression.
This table summarizes SUCLA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SUCLA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUCLA2 shows lower tumor expression in KICH, THCA, KIRC, KIRP and BRCA and higher tumor expression in CHOL. The KICH box plot shows higher SUCLA2 RNA expression in normal versus tumor tissue (log2 FC = −1.648, t-test p < 0.001).
This table shows molecular features associated with SUCLA2 in patient tissues and cancer cell lines. In patient samples, SUCLA2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SUCLA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
